- Johnson & Johnson (JNJ +0.7%) is making the rounds to companies that might be interested in buying its blood-testing division, which could fetch around $5B.
- JNJ's Ortho Clinical Diagnostics unit makes tests that can reveal a patient's blood type and screen for viruses like HIV and hepatitis C. It also makes tests that help diagnose a heart attack and assess damage to the heart.
- The testing business is part of a $46B world-wide market for in vitro diagnostics that is growing 6% - 7% a year.
- A potential deal could be wrapped up by as early as the year's end.
From other sites
at Financial Times (Apr 29, 2015)
at Nasdaq.com (Apr 27, 2015)
at Investopedia (Apr 10, 2015)
at 4-traders.com (Mar 24, 2015)
at Nasdaq.com (Mar 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs